Presentation by Emily Morgan

Peer-reviewed by Isobel Wright, Grace Chen, Bethany Medley, and Rachel Atterato

Introduction:

Ibogaine is a plant-based medicine currently being explored as a treatment for opioid use disorder (OUD). It is a naturally occurring indole alkaloid extracted from the root bark of the Tabernanthe iboga, a shrub native to rainforests in Western Africa (Schep, et al). Indigenous groups have used it safely for medicinal and religious purposes for centuries (Davis, et al). Currently, it is being investigated to remove cravings and help relieve withdrawals for opioid users (Schelp, Slaughter). However, the mechanisms of action are still novel, making it difficult to mitigate adverse side effects (Alper). While ibogaine has a history of therapeutic value, thorough clinical research is still lacking.

Discussion

Ibogaine is a plant-based medicine currently being investigated to treat opioid addiction. It originates from Western Africa and has been used for centuries medicinally and in religious ceremonies. As use of the medicine widened, it was found to be helpful in treating withdrawals associated with OUD. Recent studies have shown that it is both safe and effective in reducing post acute withdrawal syndrome. However, due to its psychoactive properties, ibogaine has been classified as a Schedule 1 drug. This brought a halt to all research within the United States and most clinical trials take place abroad. Preliminary results of these studies have appeared promising. The mechanisms of action are still novel, making it difficult to reduce negative side effects. More research is needed to determine its clinical significance in treating OUD.

References

Schep LJ, Slaughter RJ, Galea S, Newcombe D. (2016). Ibogaine for treating drug dependence. What is a safe dose?. Drug

Alcohol Dependence. 166:1-5. https://doi.org/10.1016/j.drugalcdep.2016.07.005

Davis, A. K., Barsuglia, J. P., Windham-Herman, A., Lynch, M., & Polanco, M. (2017). Subjective effectiveness of ibogaine

treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning, Journal of Psychedelic Studies, 1(2), 65-73. Retrieved Aug 8, 2020 https://akjournals.com/view/journals/2054/1/2/article-p65.xml

Alper, K., (2001) Ibogaine: A Review. The Alkaloids: Chemistry and Biology. 56: 1-38. 10.1016/s0099-9598(01)56005-8

Alper, K., Lotsof H., (2007) The Use of Ibogaine in the Treatment of Addictions. In Winkelman M., Roberts T., Psychedelic

Medicine. 43-66. Praeger Perspectives publishing group.

Goutarel, Robert., Gollnhofer, Otto., Sillians, Roger. (1993). Pharmacodynamics and Therapeutic Applications of Iboga and

Ibogaine. Psychedelics Monographs and Essays. 6: 70-111. https://ibogainedossier.com/bwiti1.html

Brown, T., (2013). Ibogaine in the Treatment of Substance Dependence. Current Drug Abuse Reviews, 6 (1): 3-16.

10.2174/15672050113109990001

Gallo, Chiara., Renzi, Paolo., Loizzi Stephano., Loizzi, Alberto., Capasso., (2009). Tabernanthe iboga : A Comprehensive

Review. Pharmacologyonline. 3: 906-920. https://pharmacologyonline.silae.it/files/newsletter/2009/vol3/91.Chiara.pdf

Alper, K., Beal D., Kaplan, C., (2001). A Contemporary History of Ibogaine in the United States and Europe. The Alkaloids:

Chemistry and Biology. 56: 249-281. 10.1016/S0099-9598(01)56018-6

Kang, Chen., Kokate T., Donevan, S., Carroll I., Rogawski. (1996). Ibogaine block of the NMDA receptor: In vitro and in

vivo studies. Neuropharmacology. 35: 4, 423-431. https://www.sciencedirect.com/science/article/abs/pii/0028390896841074

Brown,T.,Alper,K.(2017).Treatmentofopioidusedisorderwithibogaine:detoxificationanddruguseoutcomes.The

American Journal of Drug and Alcohol Abuse, 44: 24-36. 10.1080/00952990.2017.1320802

https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1320802?scroll=top&needAccess=true

OnaiviE.,AliS.,ChirwaS.,Zwiller,J.,ThiretN.,Akinshola,E.,Ishiguro.(2002).IbogaineSignalsAddictionGenesand Methamphetamine Alteration of Long-Term Potential. Annals New York Academy of Sciences. 965: 28–46. 10.1016/bs.pbr.2018.08.005

Glick,S.D.andMaisonneuve,I.M(1998).MechanismsofAntiAddictiveActionsofIbogainea.AnnalsoftheNewYork Academy of Sciences, 844: 214-226. doi:10.1111/j.1749-6632.1998.tb08237.x

Kohek,M.,Ohren,M.,Hornby,P.,Alcázar-Córcoles,M.Á.andBouso,J.C.(2020),TheIbogaineExperience:AQualitative Study on the Acute Subjective Effects of Ibogaine. Anthropol Conscious, 31: 91-119. doi:10.1111/anoc.12119

Mash, D., Craig, K., Pablo, J., Tyndale R., Ervin, F., Kamlet J., Hearn, W. (2001). Ibogaine in the treatment of heroin withdrawal. The Alkaloids: Chemistry and Biology. 56: 155-171. https://doi.org/10.1016/S0099-9598(01)56012-5

CorkeryJ.M(2018).Ibogaineasatreatmentforsubstancemisuse:Potentialbenefitsandpracticaldangers.Progressinbrain research, 242, 2 17-257. https://doi.org/10.1016/bs.pbr.2018.08.005

Marta, C.J., Ryan, W.C, Kopelowicz, A. and Koek, R.J. (2015), Mania following use of ibogaine: A cast series. Am J Addict, 24: 203-205. doi:10.1111/ajad.12209

Mash,D.C.,Duque,L.,Page,B.,&Allen-Ferdinand,K.(2018).IbogaineDetoxificationTransitionsOpioidandCocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in pharmacology, 9, 529. https://doi.org/10.3389/fphar.2018.00529

CarnicellaS,HeD.,YowellQ.,GlickS.,RonD.(2010).Noribogaine,butnot18-MC,exhibitssimilaractionsasibogaineon GDNF expression and ethanol self-administration. Addiction Biology. 15(4):424-433. 10.1111/j.1369-1600.2010.00251.